0.4882

2.36% -0.0118

Outlook Therapeutics Inc (OTLK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Outlook Therapeutics Inc stock is traded at $0.4882, with a volume of 3.09M. It is down -2.36% in the last 24 hours and down -27.88% over the past month. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Previous Close:

$0.50

Open:

$0.52

24h Volume:

3.09M

Relative Volume:

0.71

Market Cap:

$118.85M

Revenue:

$424.90K

Net Income/Loss:

$-94.02M

P/E Ratio:

-0.1965

EPS:

-2.4842

Net Cash Flow:

$-51.25M

1W Performance:

-18.48%

1M Performance:

-27.88%

6M Performance:

+80.55%

1Y Performance:

-63.57%

1-Day Range:

$0.485

$0.5326

1-Week Range:

$0.4379

$0.60

52-Week Range:

$0.1611

$2.5375

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name

Outlook Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(609) 619-3990

Address

111 S. WOOD AVENUE, ISELIN, NJ

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

OTLK's Discussions on Twitter

Compare OTLK vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OTLK Outlook Therapeutics Inc	0.4882	118.85M	424.90K	-94.02M	-51.25M	-2.4842
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-27-26	Upgrade	BTIG Research	Neutral → Buy
May-18-26	Downgrade	BTIG Research	Buy → Neutral
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight
Apr-03-23	Initiated	Guggenheim	Buy
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-22	Initiated	BTIG Research	Buy
Sep-13-22	Initiated	Chardan Capital Markets	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
May-16-19	Initiated	Oppenheimer	Outperform
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

Oct 13, 2026

Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK). - Stock Titan

Oct 13, 2026

Oct 11, 2026

Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. - www.marketscreener.com

Oct 11, 2026

Outlook Therapeutics (Nasdaq:OTLK)Stock Analysis - Simply Wall Street

Oct 11, 2026

Oct 05, 2026

Outlook Therapeutics files CMS code application and Outlook Therapeutics stock trades at EUR 0.53 - AD HOC NEWS

Oct 05, 2026

Sep 30, 2026

Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Sep 30, 2026

Sep 12, 2026

Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Australia

Sep 12, 2026

Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Canada

Sep 12, 2026

Sep 11, 2026

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - The Manila Times

Sep 11, 2026

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - marketscreener.com

Sep 11, 2026

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance

Sep 11, 2026

OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.50 - GuruFocus

Sep 11, 2026

Sep 10, 2026